A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer Clinical Trial

Official title: A Phase 3，Randomized，Open，Parallel Controlled, Multi-center Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab as a First-line Treatment on Patient With Advanced Non-squamous NSCLC

Status Recruiting

Clinical Trial Summary

This is Phase 3, randomized, open-label, parallel controlled study designed to compare the efficacy and safety of TQB2450 in combination with platinum-containing chemotherapy followed by TQB2450 plus Anlotinib versus tislelizumab in combination with platinum-containing chemotherapy followed by tislelizumab in locally advanced (stage ⅢB/ⅢC), metastatic or recurrent ( Stage IV) non-squamous NSCLC cancer. The primary endpoint is Progression Free Survival (PFS) assessed by IRC.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced Non-squamous Non-small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

• NCT number: NCT05346952
• Study type: Interventional
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: Yuankai Shi, Doctor
• Phone: 13701251865
• Email: syuankaipumc@126.com
• Status: Recruiting
• Phase: Phase 3
• Start date: January 25, 2022
• Completion date: December 2023